254 related articles for article (PubMed ID: 37650539)
41. Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation.
Taha MS; Padmakumar S; Singh A; Amiji MM
Drug Deliv Transl Res; 2020 Jun; 10(3):766-790. PubMed ID: 32170656
[TBL] [Abstract][Full Text] [Related]
42. Nanomedicines for Reactive Oxygen Species Mediated Approach: An Emerging Paradigm for Cancer Treatment.
Kwon S; Ko H; You DG; Kataoka K; Park JH
Acc Chem Res; 2019 Jul; 52(7):1771-1782. PubMed ID: 31241894
[TBL] [Abstract][Full Text] [Related]
43. The spatiotemporal journey of nanomedicines in solid tumors on their therapeutic efficacy.
Qin M; Xia H; Xu W; Chen B; Wang Y
Adv Drug Deliv Rev; 2023 Dec; 203():115137. PubMed ID: 37949414
[TBL] [Abstract][Full Text] [Related]
44. Tumor-targeted nanomedicines for cancer theranostics.
Arranja AG; Pathak V; Lammers T; Shi Y
Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
[TBL] [Abstract][Full Text] [Related]
45. Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization.
Sun Q; Zhou Z; Qiu N; Shen Y
Adv Mater; 2017 Apr; 29(14):. PubMed ID: 28234430
[TBL] [Abstract][Full Text] [Related]
46. Nanomedicines via the pulmonary route: a promising strategy to reach the target?
Guérin M; Lepeltier E
Drug Deliv Transl Res; 2024 Aug; 14(8):2276-2297. PubMed ID: 38587757
[TBL] [Abstract][Full Text] [Related]
47. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines.
Islam R; Gao S; Islam W; Šubr V; Zhou JR; Yokomizo K; Etrych T; Maeda H; Fang J
Acta Biomater; 2021 May; 126():372-383. PubMed ID: 33774199
[TBL] [Abstract][Full Text] [Related]
48. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy.
Zhou Q; Dong C; Fan W; Jiang H; Xiang J; Qiu N; Piao Y; Xie T; Luo Y; Li Z; Liu F; Shen Y
Biomaterials; 2020 May; 240():119902. PubMed ID: 32105817
[TBL] [Abstract][Full Text] [Related]
49. A Nanomedicine Structure-Activity Framework for Research, Development, and Regulation of Future Cancer Therapies.
Youden B; Jiang R; Carrier AJ; Servos MR; Zhang X
ACS Nano; 2022 Nov; 16(11):17497-17551. PubMed ID: 36322785
[TBL] [Abstract][Full Text] [Related]
50. Brave new world revisited: Focus on nanomedicine.
Fadeel B; Alexiou C
Biochem Biophys Res Commun; 2020 Nov; 533(1):36-49. PubMed ID: 32921412
[TBL] [Abstract][Full Text] [Related]
51. High drug-loading nanomedicines: progress, current status, and prospects.
Shen S; Wu Y; Liu Y; Wu D
Int J Nanomedicine; 2017; 12():4085-4109. PubMed ID: 28615938
[TBL] [Abstract][Full Text] [Related]
52. Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy.
Rahman M; Akhter S; Ahmad J; Ahmad MZ; Beg S; Ahmad FJ
Expert Opin Drug Deliv; 2015 Apr; 12(4):635-52. PubMed ID: 25439967
[TBL] [Abstract][Full Text] [Related]
53. Relevant Physicochemical Descriptors of "Soft Nanomedicines" to Bypass Biological Barriers.
Nino-Pariente A; Nebot VJ; Vicent MJ
Curr Pharm Des; 2016; 22(9):1274-91. PubMed ID: 26675217
[TBL] [Abstract][Full Text] [Related]
54. Nanomedicines for kidney diseases.
Williams RM; Jaimes EA; Heller DA
Kidney Int; 2016 Oct; 90(4):740-5. PubMed ID: 27292222
[TBL] [Abstract][Full Text] [Related]
55. Theranostic nanomedicine.
Lammers T; Aime S; Hennink WE; Storm G; Kiessling F
Acc Chem Res; 2011 Oct; 44(10):1029-38. PubMed ID: 21545096
[TBL] [Abstract][Full Text] [Related]
56. Not just for tumor targeting: unmet medical needs and opportunities for nanomedicine.
Lepeltier EA; Nuhn L; Lehr CM; Zentel R
Nanomedicine (Lond); 2015; 10(20):3147-66. PubMed ID: 26447353
[TBL] [Abstract][Full Text] [Related]
57. Nanomedicine to overcome antimicrobial resistance: challenges and prospects.
Zou W; McAdorey A; Yan H; Chen W
Nanomedicine (Lond); 2023 Feb; 18(5):471-484. PubMed ID: 37170884
[TBL] [Abstract][Full Text] [Related]
58. What nanomedicine in the clinic right now really forms nanoparticles?
Svenson S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2014; 6(2):125-35. PubMed ID: 24415653
[TBL] [Abstract][Full Text] [Related]
59. Role of Particle Size in Translational Research of Nanomedicines for Successful Drug Delivery: Discrepancies and Inadequacies.
Chan HW; Chow S; Zhang X; Kwok PCL; Chow SF
J Pharm Sci; 2023 Sep; 112(9):2371-2384. PubMed ID: 37453526
[TBL] [Abstract][Full Text] [Related]
60. Lysosomal nanotoxicity: Impact of nanomedicines on lysosomal function.
Uzhytchak M; Smolková B; Lunova M; Frtús A; Jirsa M; Dejneka A; Lunov O
Adv Drug Deliv Rev; 2023 Jun; 197():114828. PubMed ID: 37075952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
